Navigation Links
Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
Date:3/12/2010

-chron">February 2010, we announced the appointment of Felix J. Baker, Ph.D. to our Board of Directors. Dr. Baker is a managing partner of Baker Bros. Advisors, LLC, the manager and advisor to the funds of Baker Brothers Investments, Ardea's largest stockholder.
  • In January 2010, we announced positive results from the second dosing cohort of a completed Phase 2a, proof-of-concept study evaluating the serum urate (sUA) lowering effect, safety and tolerability of combining RDEA594 and allopurinol in gout patients with hyperuricemia (mean sUA level of 10.2 mg/dL). The combination of RDEA594 and allopurinol reduced sUA levels an additional 24 percent compared to allopurinol alone, and resulted in a 100 percent treatment response rate. The combination of RDEA594 and allopurinol in gout patients was well tolerated.
  • Also in January 2010, we announced positive results from the second panel of a Phase 1 drug-drug interaction and pharmacodynamic study of RDEA594 in combination with febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen and Menarini), in healthy volunteers with a mean sUA level of 7.0 mg/dL. The combination of RDEA594 with febuxostat resulted in approximately a 70 to 80 percent mean reduction in sUA levels compared to baseline, reaching mean sUA levels of 1.2 mg/dL. The combination of RDEA594 and febuxostat was well tolerated, with Grade 2 elevations of liver enzymes associated with febuxostat treatment as the only significant laboratory abnormalities.

  • Clinical Development Efforts and Important Upcoming Clinical Development Milestones'/>"/>

    SOURCE Ardea Biosciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
    2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
    3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
    4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
    5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
    6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
    7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
    8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
    9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
    10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
    11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
    (Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
    (Date:1/14/2014)... 14, 2014   NuAire , a manufacturer of ergonomically designed ... Hitachi Koki of Japan to sell ... America . NuAire will utilize its network of sales professionals ... Canada to offer assistance in application use, product benefits ...
    Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
    ... Soligenix, Inc. (Soligenix or the Company) (OTC ... biopharmaceutical company, announced today promising preliminary results from ... or BDP) in a canine gastrointestinal acute radiation ... with SGX202 demonstrated statistically significant (p=0.04) improvement in ...
    ... BOTHELL, Wash., Jan. 18, 2011 BioLife Solutions, ... announced today that it has significantly increased its ... regenerative medicine industry.  The worldwide regenerative medicine market ... hospitals, which are developing cell and tissue-based products ...
    Cached Medicine Technology:Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 2Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 3Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 4Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 5BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry 2BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry 3BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry 4BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry 5
    (Date:4/17/2014)... a review published in the April issue of ... Feinstein Institute for Medical Research, says it,s time to ... approach to treating sepsis, which kills millions worldwide ... occurs when molecules released into the bloodstream to fight ... Inflammation is necessary for maintaining good health without ...
    (Date:4/17/2014)... team has created a new technology for modifying ... travel the body and selectively target cancer and ... devices that monitor and modify human physiology is ... no existing technology enabled bioengineers to build such ... respond in a customized fashion. , "The project ...
    (Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
    (Date:4/17/2014)... 2014) The cause of neuronal death in Parkinson,s ... that neurons may be mistaken for foreign invaders and ... the way autoimmune diseases like type I diabetes, celiac ... study was published April 16, 2014, in Nature ... controversial, idea in Parkinson,s disease; but if true, it ...
    (Date:4/17/2014)... 17, 2014 By discovering a new mechanism that ... stroke, researchers at UC Irvine and the Salk Institute ... limit or prevent stroke-induced brain damage. , A complex ... of death and primary reason for disability in the ... stroke and lets blood-borne material into the brain, causing ...
    Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
    ... Reporter , TUESDAY, Feb. 22 (HealthDay News) -- Nitroglycerin ... counter bone loss, a new study suggests. As ... is increasing. Nitroglycerin appears to increase bone density ... over newer and more costly drugs, the researchers noted. ...
    ... new type of nanoparticle that could safely and effectively deliver ... The new particles, described in the Feb. 20 issue of ... can carry synthetic versions of proteins normally produced by viruses. ... to that produced by live virus vaccines but should ...
    ... (Feb. 22, 2011) Three American College of Radiology ... the ACR Board of Chancellors will outline strategies for ... minimize medical radiation exposure at a Feb. 24, 25 ... "NIH Summit to Focus on Management of Radiation Dose ...
    ... NY) In an advance that could improve battlefield ... of Medicine of Yeshiva University have used tiny ... loss. Nanoparticles containing nitric oxide (NO) were infused into ... circulation and protect vital organs. The research was reported ...
    ... TUESDAY, Feb. 22 (HealthDay News) -- The increasingly commonplace ... labor for convenience rather than for medical necessity entails ... suggests. The new report, which highlights the negative ... first-time mothers, indicates that going that route increases the ...
    ... respond differently to their crying babies than do non-depressed ... at the University of Oregon, is much more muted ... An infant crying is normal, but how mothers respond ... professor of psychology. For years, Ablow has studied the ...
    Cached Medicine News:Health News:Nitroglycerin Ointment Might Strengthen Bones 2Health News:Nitroglycerin Ointment Might Strengthen Bones 3Health News:MIT engineers design new nanoparticle that could lead to vaccines for HIV, malaria, other diseases 2Health News:MIT engineers design new nanoparticle that could lead to vaccines for HIV, malaria, other diseases 3Health News:ACR commission and committee chairs and former board chair to present at NIH Radiation Dose Summit 2Health News:Nanoparticles increase survival after blood loss 2Health News:Induced Labor Linked to Raised Risks for First-Time Moms 2Health News:Crying baby draws blunted response in depressed mom's brain 2Health News:Crying baby draws blunted response in depressed mom's brain 3
    ... The programmer for the ITREL 3 ... programmer and the Model 7457 MemoryMod ... indicated for the treatment of chronic nausea ... drug therapies are not providing adequate relief ...
    ... Rapid diagnosis of influenza A ... important due to the availability ... diagnosis of influenza using Clearview ... can lead to reduced hospital ...
    ... ability of the visual system to ... are,some pathological conditions that reduce contrast ... test will help in the identification ... and reduced visual acuity often occur ...
    ...
    Medicine Products: